Structure Therapeutics, Inc. Sponsored ADR (GPCR) Price & Analysis

Compare

1,206 Followers

GPCR Stock Chart & Stats

$62.98

-$0.32(-1.18%)

At close: Jan 08 4:00 PM EST

$62.98

-$0.32(-1.18%)

Day’s Range― - ―

52-Week Range$13.22 - $94.90

Previous CloseN/A

Volume219.80K

Average Volume (3M)929.03K

Market Cap

$4.45B

Enterprise Value$2.83B

Total Cash (Recent Filing)$1.45B

Total Debt (Recent Filing)$6.49M

Price to Earnings (P/E)―

Beta1.20

Next Earnings

May 07, 2026

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.17

Shares Outstanding70,639,190

10 Day Avg. Volume787,508

30 Day Avg. Volume929,029

Financial Highlights & Ratios

PEG Ratio-11.37

Price to Book (P/B)2.72

Price to Sales (P/S)0.00

P/FCF Ratio-18.23

Enterprise Value/Market Cap0.64

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.12K

Enterprise Value/Ebitda-17.94

Forecast

1Y Price Target

$109.23

Price Target Upside73.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)-1.92

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DifferentiationPositive Phase 2b results from the ACCESS program demonstrated substantial weight loss and clinical differentiation for aleniglipron, supporting plans for an End-of-Phase II meeting with the FDA and a clear path to a Phase 3 registrational program.

Commercial OpportunityStrong market uptake of oral GLP-1 pills and aleniglipron's manufacturing cost advantage create a sizable commercial opportunity by enabling competitive pricing and addressing demand for once-daily oral obesity treatments.

Pipeline And Business DevelopmentFirst-in-human data for the company's oral small-molecule amylin candidate and broad partnership interest could materially expand the pipeline and attract biopharma partners for registrational and commercial support.

Bears Say

Competitive PressureA crowded obesity field with several large pharmaceutical programs showing strong amylin and oral peptide results increases competition and could pressure market share and pricing for smaller developers like the company.

Execution And Development RiskDelivery of upcoming clinical readouts and alignment with regulators remain critical, creating execution risk that could delay progression to pivotal studies if trials or regulatory discussions do not meet expectations.

Tolerability And AdherenceNotable vomiting rates in some treatment cohorts and a slower titration profile raise tolerability and real-world adherence concerns that may limit patient uptake compared with faster-titrating oral competitors.

Structure Therapeutics, Inc. Sponsored ADR News

Structure Therapeutics price target lowered to $113 from $120 at Citizens

Citizens analyst Jonathan Wolleben lowered the firm’s price target on Structure Therapeutics (GPCR) to $113 from $120 and...

2d ago

GPCR

Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat

The major averages were broadly lower near noon as tech stocks continue to decline and as investors continue...

29d ago

Structure Therapeutics emerges as top M&A target for big pharma, Axios says

Structure Therapeutics (GPCR), which his working on next-gen oral obesity medication, has emerged as the next top M&A...

29d ago

GPCR

Buy Rating on Structure Therapeutics: Strong Phase II Data and Upcoming Late‑Stage Catalysts Support Upside for Oral GLP‑1 Aleniglipron

William Blair analyst Andy Hsieh has reiterated their bullish stance on GPCR stock, giving a Buy rating on...

2d ago

GPCR

Structure Therapeutics price target raised to $105 from $65 at JPMorgan

JPMorgan raised the firm’s price target on Structure Therapeutics (GPCR) to $105 from $65 and keeps an Overweight...

1M ago

GPCR

Structure Therapeutics price target raised to $140 from $90 at Guggenheim

Guggenheim raised the firm’s price target on Structure Therapeutics (GPCR) to $140 from $90 and keeps a Buy...

1M ago

GPCR

Structure Therapeutics moved to Buy rating at Goldman Sachs

Goldman Sachs moved Structure Therapeutics (GPCR) to Buy rating and $102 price target from Early Stage Biotech. The...

1M ago

LLY

GPCR

Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher

Shares of several names in the obesity-drug space, including Viking Therapeutics (VKTX), Terns Pharmaceuticals (TERN), and Structure Therapeutics...

2M ago

LLY

NVO

Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports

Novo Nordisk (NVO) is back on the hunt for deals to boost its obesity portfolio after losing U.S....

2M ago

LLY

NVO

Structure Therapeutics rises 14.1%

Structure Therapeutics (GPCR) is up 14.1%, or $9.79 to $79.15. Published first on TheFly – the ultimate source...

2M ago

GPCR

Validating IP, Extending Runway: Why Structure Therapeutics’ Oral GLP‑1 Platform Supports a Buy Rating

Analyst Patrick Dolezal of LifeSci Capital maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, reducing the...

2M ago

GPCR

Structure Therapeutics inks major GLP-1 licensing deal

Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) has issued an update. On December 30, 2025, Gasherbrum Bio,...

2M ago

GPCR

Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright

H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Structure Therapeutics (GPCR) to $90 from $60...

2M ago

GPCR

Structure Therapeutics Announces $650 Million Public Offering

An update from Structure Therapeutics, Inc. Sponsored ADR ( ($GPCR) ) is now available. On December 9, 2025,...

3M ago

GPCR

GPCR FAQ

What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?

Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $94.90 in the past 12 months.

What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?

Structure Therapeutics, Inc. Sponsored ADR’s market cap is $4.45B.

When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?

Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is May 07, 2026 which is in 67 days.

How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?

Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Feb 26, 2026. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of -$0.057 by $0.227.

Is Structure Therapeutics, Inc. Sponsored ADR overvalued?

According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?

Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.

What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?

Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.39.

How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?

Structure Therapeutics, Inc. Sponsored ADR has 70,639,190 shares outstanding.

What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?

Structure Therapeutics, Inc. Sponsored ADR reported an EPS of $0.17 in its last earnings report, beating expectations of -$0.057. Following the earnings report the stock price went down -2.734%.

Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?

Currently, no hedge funds are holding shares in GPCR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score

Outperform

Fundamentals

Return on Equity

-25.31%

Trailing 12-Months

Asset Growth

-10.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Structure Therapeutics, Inc. Sponsored ADR

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Earnings & Revenues

Historic Earnings Reports

GPCR Stock 12 Month Forecast

Average Price Target

$109.23

▲(73.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","141":"$141","45.75":"$45.8","77.5":"$77.5","109.25":"$109.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":109.23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$109.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,45.75,77.5,109.25,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.84,93.69846153846154,97.55692307692308,101.41538461538462,105.27384615384615,109.13230769230769,112.99076923076923,116.84923076923077,120.70769230769231,124.56615384615384,128.42461538461538,132.28307692307692,136.14153846153846,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.84,91.33153846153847,92.82307692307693,94.3146153846154,95.80615384615385,97.29769230769232,98.78923076923077,100.28076923076924,101.77230769230769,103.26384615384616,104.75538461538461,106.24692307692308,107.73846153846154,{"y":109.23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.84,89.85230769230769,89.86461538461539,89.87692307692308,89.88923076923078,89.90153846153846,89.91384615384615,89.92615384615385,89.93846153846154,89.95076923076923,89.96307692307693,89.97538461538461,89.98769230769231,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.57,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.84,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >